Scribe Therapeutics’ Research Collaboration With Biogen Inc.


Fenwick & West LLP advised Scribe Therapeutics Inc. on the deal.

Scribe Therapeutics Inc., a company focused on engineering the most advanced platform for CRISPR-based genetic medicine, announced its research collaboration with Biogen Inc. (NASDAQ: BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS).

Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need. Scribe will receive $15 million upfront and is eligible for more than $400 million in potential development and commercial milestone payments between the two targets of interest. Scribe is also eligible to receive tiered, high single digit to sub-teen royalties.

Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company products address diseases such as multiple sclerosis, non-hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.

The Fenwick transaction team included life sciences partner Stefano Quintini (Picture) and counsel Claire O’Callaghan.

Involved fees earner: Claire O’Callaghan – Fenwick & West LLP; Stefano Quintini – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Scribe Therapeutics Inc.;

Author: Ambrogio Visconti